Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event…

For the FDA, engagement with patients, caregivers and patient advocacy organizations is a vital part of the drug development and review process. However, how that engagement happens can determine how successful it is. This was the key question addressed by the “Practices and Principles: Navigating…

Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors…

On Tuesday morning at the BIO Investor Forum, leaders from top companies at the forefront of gene therapy innovation assembled to discuss successful approaches, challenges in protein delivery, and the future of expanding this class of medicines. Gene therapies have the potential to increase the…

BIO has released a new and improved mobile app for the BIO One-on-One Partnering™ system. After intensive surveys and interviews with attendees who have engaged in partnering at BIO business development & investor events around the world, we revamped our partnering mobile app to make the…

The 5th BIO Latin America was held September 3-4 in the largest metropolis in the Western Hemisphere - Sao Paulo, Brazil. The BIO Latin America Conference, co-hosted by BIO and Biominas Brazil, has solidified itself as the premier life sciences meeting in the Latin America, welcoming over 675…

Keith Ignotz knows the power of a good story. The President & CEO of OcuMedic—an early stage biotech company developing a novel pre-and post-eye surgery treatment to replace eye drops—has made significant inroads telling the OcuMedic story since he assumed his role in early 2018. Some of his…

Whether you come to the Bay Area for the entrepreneurial talent, venture capital investment or biotech innovation, this trifecta conjures the perfect storm for regional economic success. The enduring strength of the Northern California life science cluster attracts small biotech startups, which are…

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in…

Since the 1950s the Cavendish variety has held a monopoly on the banana market. But its dominance is not the result of taste or preference. Rather, grocery stores are stocked with the Cavendish variety because they are disease resistant. Specifically, they are resistant to Fusarium, a strain of…